Skip to main content
Top
Published in: Journal of Clinical Immunology 3/2022

01-04-2022 | Thymoma | Commentary

In memoriam: Stephen J Seligman, MD

Adverse reactions to the yellow fever vaccine: from epidemiological risk factors to causes and mechanisms

Authors: Jean-Laurent Casanova, Qian Zhang, Paul Bastard, Emmanuelle Jouanguy

Published in: Journal of Clinical Immunology | Issue 3/2022

Login to get access

Excerpt

Steve J Seligman (2/4/1931–11/11/2021) has passed away at the age of 90 years. In 2011, he joined our laboratory at the Rockefeller University, New York, as an Adjunct Professor, his primary affiliation remaining New York Medical College, Valhalla, where he had been a Research Professor since 2001. Most of his career was spent at SUNY, Downstate Medical Center, Brooklyn, where he had been an Associate (1968–1981), Full Professor of Medicine (1981–2000), and then finally Professor Emeritus (2000–2021). Before that, he was a Fellow (1961–1963) and Assistant Professor in Medicine (1963–1968) at UCLA (1961–1963). He trained as a Resident at Cornell Bellevue Hospital (1956–1957), Tufts Boston City Hospital (1959–1960), and Boston Veterans Administration (1960–1961), after attending medical school at NYU (1952–1956) and college at Harvard University (1948–1952). Importantly, he also served with the Public Health Service as a USPHS Epidemic Intelligence Officer at UCLA and USC from 1957 to 1959. These two years triggered his life-long interest in the global epidemiology of infectious diseases. …
Literature
1.
go back to reference Marianneau P, Georges-Courbot M, Deubel V. Rarity of adverse effects after 17D yellow-fever vaccination. Lancet. 2001;358(9276):84–5.CrossRefPubMed Marianneau P, Georges-Courbot M, Deubel V. Rarity of adverse effects after 17D yellow-fever vaccination. Lancet. 2001;358(9276):84–5.CrossRefPubMed
2.
go back to reference Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358(9276):91–7.CrossRefPubMed Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358(9276):91–7.CrossRefPubMed
3.
go back to reference Bastard P, Michailidis E, Hoffmann HH, Chbihi M, Le Voyer T, Rosain J, et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med. 2021;218(4):e20202486.CrossRefPubMedPubMedCentral Bastard P, Michailidis E, Hoffmann HH, Chbihi M, Le Voyer T, Rosain J, et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med. 2021;218(4):e20202486.CrossRefPubMedPubMedCentral
4.
go back to reference Hernandez N, Bucciol G, Moens L, Le Pen J, Shahrooei M, Goudouris E, et al. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J Exp Med. 2019;216(9):2057–70.CrossRefPubMedPubMedCentral Hernandez N, Bucciol G, Moens L, Le Pen J, Shahrooei M, Goudouris E, et al. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J Exp Med. 2019;216(9):2057–70.CrossRefPubMedPubMedCentral
5.
go back to reference Duncan CJ, Mohamad SM, Young DF, Skelton AJ, Leahy TR, Munday DC, et al. Human IFNAR2 deficiency: lessons for antiviral immunity. Sci Transl Med. 2015;7:307-307ra154.CrossRef Duncan CJ, Mohamad SM, Young DF, Skelton AJ, Leahy TR, Munday DC, et al. Human IFNAR2 deficiency: lessons for antiviral immunity. Sci Transl Med. 2015;7:307-307ra154.CrossRef
6.
go back to reference Gothe F, Howarth S, Duncan CJ, Hambleton S. Monogenic susceptibility to live viral vaccines. Curr Opin Immunol. 2021;72:167–75.CrossRefPubMed Gothe F, Howarth S, Duncan CJ, Hambleton S. Monogenic susceptibility to live viral vaccines. Curr Opin Immunol. 2021;72:167–75.CrossRefPubMed
7.
go back to reference Sutton AL, Smithwick EM, Seligman SJ, Kim D-S. Fatal disseminated herpesvirus hominis type 2 infection in an adult with associated thymic dysplasia. Am J Med. 1974;56(4):545–53.CrossRefPubMed Sutton AL, Smithwick EM, Seligman SJ, Kim D-S. Fatal disseminated herpesvirus hominis type 2 infection in an adult with associated thymic dysplasia. Am J Med. 1974;56(4):545–53.CrossRefPubMed
8.
go back to reference Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet. 2004;363(9426):2073–5.CrossRefPubMed Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet. 2004;363(9426):2073–5.CrossRefPubMed
9.
go back to reference Seligman SJ, Gould EA. Safety concerns with regard to live attenuated flavivirus vaccines. J Infect Dis. 2008;198(5):794–5.CrossRefPubMed Seligman SJ, Gould EA. Safety concerns with regard to live attenuated flavivirus vaccines. J Infect Dis. 2008;198(5):794–5.CrossRefPubMed
10.
go back to reference Poyhonen L, Bustamante J, Casanova JL, Jouanguy E, Zhang Q. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. J Clin Immunol. 2019;39(4):376–90.CrossRefPubMedPubMedCentral Poyhonen L, Bustamante J, Casanova JL, Jouanguy E, Zhang Q. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. J Clin Immunol. 2019;39(4):376–90.CrossRefPubMedPubMedCentral
11.
go back to reference Eidex RB. History of thymoma and yellow fever vaccination. The Lancet. 2004;364:9438–936.CrossRef Eidex RB. History of thymoma and yellow fever vaccination. The Lancet. 2004;364:9438–936.CrossRef
13.
go back to reference Seligman SJ. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014;32(44):5769–75.CrossRefPubMed Seligman SJ. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014;32(44):5769–75.CrossRefPubMed
14.
go back to reference Seligman SJ, Cohen JE, Itan Y, Casanova JL, Pezzullo JC. Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data. Am J Trop Med Hyg. 2014;90(2):267–71.CrossRefPubMedPubMedCentral Seligman SJ, Cohen JE, Itan Y, Casanova JL, Pezzullo JC. Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data. Am J Trop Med Hyg. 2014;90(2):267–71.CrossRefPubMedPubMedCentral
15.
go back to reference Seligman SJ, Casanova JL. Yellow fever vaccine: worthy friend or stealthy foe? Expert Rev Vaccines. 2016;15(6):681–91.CrossRefPubMed Seligman SJ, Casanova JL. Yellow fever vaccine: worthy friend or stealthy foe? Expert Rev Vaccines. 2016;15(6):681–91.CrossRefPubMed
16.
go back to reference Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med. 2014;211(11):2137–49.CrossRefPubMedPubMedCentral Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med. 2014;211(11):2137–49.CrossRefPubMedPubMedCentral
17.
go back to reference Casanova JL, Abel L. Mechanisms of viral inflammation and disease in humans. Science. 2021;374(6571):1080–6.CrossRefPubMed Casanova JL, Abel L. Mechanisms of viral inflammation and disease in humans. Science. 2021;374(6571):1080–6.CrossRefPubMed
18.
go back to reference Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:6515 eabd4585.CrossRefPubMed Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:6515 eabd4585.CrossRefPubMed
19.
go back to reference Panem S, Check IJ, Henriksen D, Vilcek J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J Immunol. 1982;129(1):1–3.PubMed Panem S, Check IJ, Henriksen D, Vilcek J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J Immunol. 1982;129(1):1–3.PubMed
20.
go back to reference Meager A, Vincent A, Newsom-Davis J, Willcox N. Spontaneous neutralising antibodies to interferon–alpha and interleukin-12 in thymoma-associated autoimmune disease. Lancet. 1997;350(9091):1596–7.CrossRefPubMed Meager A, Vincent A, Newsom-Davis J, Willcox N. Spontaneous neutralising antibodies to interferon–alpha and interleukin-12 in thymoma-associated autoimmune disease. Lancet. 1997;350(9091):1596–7.CrossRefPubMed
21.
go back to reference Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6(62):eabl4340.CrossRefPubMedPubMedCentral Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6(62):eabl4340.CrossRefPubMedPubMedCentral
22.
go back to reference Seligman SJ. Future roles of subspecialists. Ann Intern Med. 1996;125(6):524 (author reply 524–525).CrossRefPubMed Seligman SJ. Future roles of subspecialists. Ann Intern Med. 1996;125(6):524 (author reply 524–525).CrossRefPubMed
23.
go back to reference Seligman SJ, Rapp F. A variant of measles virus in which giant cell formation appears to be genetically determined. Virology. 1959;9:143–5.CrossRefPubMed Seligman SJ, Rapp F. A variant of measles virus in which giant cell formation appears to be genetically determined. Virology. 1959;9:143–5.CrossRefPubMed
Metadata
Title
In memoriam: Stephen J Seligman, MD
Adverse reactions to the yellow fever vaccine: from epidemiological risk factors to causes and mechanisms
Authors
Jean-Laurent Casanova
Qian Zhang
Paul Bastard
Emmanuelle Jouanguy
Publication date
01-04-2022
Publisher
Springer US
Keywords
Thymoma
Thymoma
Published in
Journal of Clinical Immunology / Issue 3/2022
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-021-01204-2

Other articles of this Issue 3/2022

Journal of Clinical Immunology 3/2022 Go to the issue